<div id="readability-page-1"><p>Bar Harbor Wealth Management lowered its position in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 5.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 206,778 shares of the company's stock after selling 11,018 shares during the quarter. Johnson &amp; Johnson comprises approximately  2.3% of Bar Harbor Wealth Management's holdings, making the stock its 7th largest holding. Bar Harbor Wealth Management's holdings in Johnson &amp; Johnson were worth $38,341,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Clark Asset Management LLC increased its stake in  Johnson &amp; Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company's stock worth $1,357,000 after buying an additional 3,025 shares during the period.  Treasurer of the State of North Carolina lifted its stake in shares of  Johnson &amp; Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock worth $188,638,000 after acquiring an additional 94,957 shares in the last quarter.  Avanza Fonder AB boosted its holdings in  Johnson &amp; Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after purchasing an additional 6,566 shares during the last quarter.  Talbot Financial LLC grew its stake in  Johnson &amp; Johnson by 4.6% during the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company's stock valued at $25,667,000 after purchasing an additional 6,143 shares in the last quarter.  Finally, Winnow Wealth LLC purchased a new stake in  Johnson &amp; Johnson during the 2nd quarter worth approximately $295,000. 69.55% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts have recently weighed in on JNJ shares. Wall Street Zen raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, September 13th. UBS Group increased their price objective on shares of Johnson &amp; Johnson from $190.00 to $214.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, October 14th. Cowen  reissued a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a report on Tuesday, October 14th. Royal Bank Of Canada  set a $240.00 target price on shares of Johnson &amp; Johnson in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus increased their price target on shares of Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued  a Buy rating and nine have assigned  a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $210.25.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p><b>Read Our Latest Report on JNJ</b></p><h2>Johnson &amp; Johnson Stock Down 0.1%</h2><p>Shares of NYSE:JNJ opened at $207.54 on Friday. The company's fifty day moving average is $199.67 and its two-hundred day moving average is $180.86. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson &amp; Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The stock has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. </p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%.  Equities analysts anticipate that  Johnson &amp; Johnson will post 10.58 EPS for the current year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><p>The business also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio  is presently 50.19%. </p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.  </p><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bar Harbor Wealth Management reduced its stake in Johnson & Johnson by 5.1% in Q3, selling 11,018 shares, now holding 206,778 shares valued at $38.34 million. JNJ is 2.3% of their portfolio. Other investors adjusted their JNJ holdings, with analysts giving a "Moderate Buy" rating and a $210.25 target price. JNJ's stock opened at $207.54, with a market cap of $500.02 billion.</p>

Bar Harbor Wealth Management Sells 11,018 Shares of Johnson & Johnson $JNJ